Oligo Medic was founded in 2010 by biomaterials experts who have developed the first polysaccharide thermogelling implants for biomedical applications1, with a vision to provide minimally invasive solutions that fit seamlessly within the clinical workflow.

The company's leading technology platform2 is a gelling composition with the following fundamental characteristics:

  • Biocompatible: it can be administered anywhere in the body without eliciting any adverse tissue reaction. Its pH and osmolarity are physiological, and it allows excellent cell viability.
  • Thermogelling: Applied through standard needles, it solidifies at the temperature of the body. This allows it to be administered as an implant with minimal harm to the patient, bypassing the need for surgical implantation or e.g. UV crosslinking.
  • Bioadhesive: Due to charges at the molecular level, it electrostatically adheres to mucous surfaces, allowing for a precise application at the intended location, bypassing the need for fibrin or other gluing material.
  • Biodegradable: Once inside the body, it is slowly degraded into constituent molecules that are native to the human body.

These properties make for an ideal implant to treat articular cartilage lesions. Cartilage loss is a major debilitating and prevalent condition that can originate from osteoarthritis or traumatic events. This important clinical need is presently primarily addressed by total joint replacement (prosthesis) and other costly/invasive procedures. Preventive approaches including viscosupplementation (hyaluronic acid injections) have showed limited success.

Oligo Medic has focused its efforts developing its first product JointRepTM as a minimally-invasive solution to cartilage loss. It obtained the CE mark in 2013 and is presently manufacturing and commercializing its product for several markets across Europe, Latin America, the Middle East, South East Asia and New Zealand. The company is also preparing a clinical trial for JointRepTM in the United States.

Oligo Medic operates under a Quality Management System which complies with the requirements of ISO 13485:2016.

The company has started work using its technology to address intervertebral disc degeneration. Other future projects include the local delivery of stem cells for other applications in regenerative medecine, localized drug-delivery, wound healing, cosmetic care, and others.

1 Chenite A, Chaput C, Combes C, Selmani A, Jalal F. Temperature-controlled pH-dependent formation of ionic polysaccharide gels US Patent 6,344,488. Feb 5, 2002

2 Chenite A, Selmani A. Highly Biocompatible Dual Thermogelling Chitosan/Glucosamine Salt Compositions. US Patent 8,506,972. Mar 1, 2012


Obtained license from TGA for JointRep™ in Australia.

Obtained license from Health Canada for JointRep™.

Preliminary steps taken toward procedures with FDA for market approval in the US.

Gaining market penetration in Europe, ANZ regions, Middle East, South East Asia, and Latin America.

Very favorable results on clinical trial published in Journal of Clinical Orthopedics and Trauma.

Other clinical trials on different indications are planned and will be disclosed when protocols are defined.

Initiated European controlled clinical trial: 69 patients, and comparing microfracture to microfracture & JointRep™.

Initial experimentation with JointRep™ and microfracture. Results are highly favorable with fast pain relief, accelerated recovery time, and nice cartilage regrowth.
Structured OligoMedic for distribution partnership and initiated case studies and post market evaluation.
Manufacturing, packaging, and shipping processes defined. Obtained CE mark in October.

Follow up case series on Health Canada SAP.

Creation of Oligo Medic Inc. Development of technology platform. Bench testing and pre-clinical characterization. Initiated Health Canada Special Access Program ("SAP"). Successful first-in-man JointRep™ operation. 

Management Team

Amine Selmani, PhD

Executive Chairman
Dr. Amine Selmani holds a PhD in Material Sciences (1985) from the University of Montreal. After three years as post-doc positions in different universities, he joined the prestigious engineering school ‘Ecole Polytechnique de Montreal’ as a Professor. Dr. Selmani’s research in biomaterials and biotechnologies led him to incorporate BioSyntech in 1995 and be part of its executive team as CEO and Chairman of the Board for close to 10 years (1995-2004). During his tenure, Dr. Selmani was able to take this biotechnology company public on both Nasdaq and TSX.


Also, Dr. Selmani founded in 1992 POLNOR (Polytechnique-Noranda) group of around 30 engineers and professionals, with the mandateto provide higher value to the Noranda amorphous silicon and other products (produced in very small quantities). Big budgets coming from Noranda, Natural Sciences and Engineering Research Council of Canada, 3M and The Ecole Polytechnique de Montreal allowed the development of High Resolution Digital Mamograph X-rays plates that are today used in most of radiology centers and commercialized by the well-known company in the field, Analogic. Few employees coming from the same project created a company (5N Plus), now leader in the world of high-specialized materials. The company is listed on the TSX, Toronto.

Jerett Creed

Chief Executive Officer
Mr. Creed has more than 20 years of medtech experience spanning multiple disease sectors and leadership roles with a strong focus on international commercialization, capital markets and business development. Mr. Creed has participated in a leadership role on transactions exceeding $650 million in M&A activity including 2 public offerings. Most recently Mr. Creed was in charge of launching Oligo Medic's JointRep™ product throughout Latin America. Prior to that, Mr. Creed was founder and CEO of Cardigant Medical, a formerly public company focused on the development and commercialization of novel peptide mimetics for treating vascular disease. Before that Mr. Creed was interim Chief Financial Officer for a publicly traded oil and gas company providing leadership through multiple acquisitions and one divestiture. Mr. Creed began his career with Johnson and Johnson initially focused on manufacturing and product development of early angioplasty balloons and bare metal stents ultimately spending more than a decade with the company finishing his tenure as Director of Business Development for an internally funded stem cell based incubator. Mr. Creed holds a Master of Science degree in Accounting and a Bachelor of Science degree in Engineering both from the University of Miami.

Abdellatif Chenite, PhD

Chief Technology Officer
Dr Chenite has the distinction of being co-founder of Oligo Medic and inventor of its technology platform.  He successfully led the first company product from conception through to manufacturing completion. Dr Chenite is an accomplished scientist and inventor, with many patents and relevant publications, focused on the development of innovative biomaterial devices for biomedical technologies. His impressive array of knowledge and technology skills is a real asset for the company.


Dr Chenite obtained a Ph.D. in Polymer Chemistry, in1992, from the University of Montréal, and immediately after his graduation he was hired a Research Associate at the National Research Council, in Ottawa, Canada, where he worked during 3 years. In 1996, he joined Biosyntech as research director and he was an essential contribution to the company success by inventing BST-Gel technology platform early in 1998. He has published more than 35 peer-reviewed scientific articles and authored patent applications for numerous distinct inventions.

Cyril Chaput, PhD, MBA

Cyril Chaput, PhD, MBA,has more than 15 years of experience as a manager in Life Science and Biotechnological companies. Cyril Chaput has biomedical engineering and biomaterials background, and holds several patents and scientific publications. He has been involved in R&D, intellectual property management, product management and business development in various Biotech and medical technology companies.


Cyril Chaput has been involved in the Biomaterial platforms development at Bio Syntech Canada, and has been IP and Business Development manager and Product manager for the Medical Device company, Angiogene Inc. In addition to his extensive work experience, Mr. Chaput holds a PhD in biomedical engineering from the EcolePolytechnique de Montreal, and a MBA in Bio-industries Management from the UQAM in Canada.

Alberto Restrepo, MD

Chief Medical Officer
Alberto Restrepo
Chief Medical Officer

Dr. Restrepo is an Orthopaedic Surgeon who after more than 20 years of a successful career as an arthroscopic surgeon, vice dean of the Universidad de La Sabana Medical School in his native Bogota (Colombia), Executive Secretary and Board member for the Colombian Orthopaedic Association (SCCOT) for several years, and KOL and international lecturer for Howmedica, Stryker and Genzyme in the domains of external fixation, bone lengthening, viscosupplementation and cartilage repair, was appointed in October 2005 by the start-up called BioSyntech (issued from the Ecole Polytechnique de Montreal) to set up and manage the Medical Affairs of the company. He contributed with his medical expertise and management skills to the success of the project BST-CarGel on cartilage repair. After its acquisition by Piramal Life Sciences, he managed both the clinical and medical departments. He was part of the reduced management team who successfully obtained the CE Mark, Canadian, Australian as well as other countries approval for the chitosan based product BST-CarGel, as well as its reimbursement in several countries. He had a pivotal role in the two Level 1 successful RCTs for cartilage repair with BST-CarGel. He set up the medical networking for its commercialization in Europe, Canada, LATAM, India and Australia/New Zealand, and participated actively in the team which designed the marketing and training strategies to introduce the technology worldwide. He is fluent in English, French and Spanish (his mother tongue). Dr. Restrepo also holds a degree in Medical Education from Universidad de La Sabana (2002) and a PDD (Programa de Desarrollo Directivo) from INALDE Business School (1999). His network of colleagues includes top KOLs in Canada/USA, Europe, LATAM, India and Australia/New Zealand.

Monique Jarry

VP Finance & Human Resources
Mrs. Monique Jarry
VP Finance & Corporate Development

Ms Jarry holds a BA and MA (1991) from University of Montreal. She implemented many accounting systems in public companies listed in Nasdaq BB and on TSX. Ms. Jarry supervised all the financial aspects of a private investment company from 1992 until 2010, when she joined Oligomedic as a VP Finances.

Sam Alexandre Selmani, Ph.D

VP Product Development
Sam joined the company in 2017 after completing his PhD in physics, and has held a variety of operational roles since. He now coordinates the company’s day-to-day operations and leads the company’s product pipeline projects as well as the scale-up of its manufacturing capabilities.